Publications
& Posters

We are proud to contribute to the latest cancer research through scientific publications and medical meetings.

December 2019

Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies

Mesa et al. ASH, December 2019

December 2019

PACIFICA: A Randomized Phase 3 Study of Pacritinib vs. Physician’s Choice in Patients with Myelofibrosis and Severe Thrombocytopenia

Harrison et al. ASH, December 2019

December 2019

Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib

O’Sullivan et al. ASH, December 2019

December 2019

The Oral JAK2/IRAK1 Inhibitor Pacritinib Demonstrates Spleen Volume Reduction in Myelofibrosis Patients Independent of JAK2 V617F Allele Burden

Verstovsek et al. ASH, December 2019

March 2018

Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis (PERSIST 2)

Mascarenhas et al. JAMA Oncology, March 2018

March 2017

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Mesa et al. Lancet Haematology, March 2017

WORKING TOGETHER TO MAKE A DIFFERENCE FOR PATIENTS

SEE OPEN JOBS